Literature DB >> 15756579

Relationship of eye burns with calcifications of the cornea?

Norbert Franz Schrage1, Sirpa Kompa, Bettina Ballmann, Martin Reim, Stephanie Langefeld.   

Abstract

INTRODUCTION: The clinical pattern of corneal calcification has been considered to be a part of chronic eye diseases, such as uveitis, severe glaucoma, keratitis and eye burns. Since, in some cases of eye burns, we have found corneal calcifications to be related to the initial calciferous caustic agents and to the use of phosphate-buffer-containing fluids, we have reviewed our files of clinical eye burns for the incidence and appearance of corneal calcification.
METHODS: A total of 176 burnt eyes of 98 patients suffering from severe eye burns were retrospectively reviewed. The following data set was acquired: the type of caustic agent, the time of the burns, the delay and type of immediate treatment and the time and type of first aid, the subsequent medication, the clinical grading and the later results.
RESULTS: Calciferous burning agents and corneal calcification are correlated (P<0.01). Initial single rinsing with phosphate does not produce corneal calcification (P=0.134). There is evidence that corneal calcifications are correlated with chronically administered phosphate-buffered eye drops (P<0.005). DISCUSSION: Eye burns followed by calcifications follow two different major patterns: the corrosive substance contained calcium or the continued therapy was applied with phosphate-buffered eye drops. We present case reports of three different types of eye burns and later therapy resulting in corneal calcification. Corneal calcifications are presumably related to longer-lasting phosphate application. One suspicious mechanism is the low content of calcium ion stabilizing proteins such as hyaluronate or fetuin in treatments for severe eye burns. The exceeding of the solubility product of Ca(2+) and PO(4) (-) results in the precipitation of calcium phosphates. In cases of chronic corneal disturbance, we recommend the elimination of phosphate-buffered medications to prevent corneal calcification.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756579     DOI: 10.1007/s00417-004-1089-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  14 in total

1.  Unsuccessful excimer laser phototherapeutic keratectomy. Clinicopathologic correlation.

Authors:  J M McDonnell; J J Garbus; P J McDonnell
Journal:  Arch Ophthalmol       Date:  1992-07

2.  The corneal stroma: an inhomogeneous structure.

Authors:  S Langefeld; M Reim; C Redbrake; N F Schrage
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-08       Impact factor: 3.117

3.  Particulate matter contamination in the corneal stroma of severe eye burns in humans.

Authors:  N F Schrage; M Reim; W G Burchard
Journal:  Lens Eye Toxic Res       Date:  1990

4.  Corneal silver deposits following Crede's prophylaxis an examination with electron dispersive x-ray analysis (EDX-analysis) and scanning electron microscope (SEM).

Authors:  G Schirner; N F Schrage; S Salla; C Teping; M Reim; W G Burchard; B Schwab
Journal:  Lens Eye Toxic Res       Date:  1990

5.  Mineral analysis in experimental corneal scars. An EDAX study.

Authors:  S Bonafonte; J N Fernandez del Cotero; A Aguirre Vila-Coro
Journal:  Cornea       Date:  1988       Impact factor: 2.651

6.  Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin.

Authors:  W Jahnen-Dechent; C Schäfer; A Heiss; J Grötzinger
Journal:  Z Kardiol       Date:  2001

7.  Calcific band keratopathy associated with the use of topical steroid-phosphate preparations.

Authors:  M J Taravella; R D Stulting; T H Mader; R W Weisenthal; S L Forstot; L D Underwood
Journal:  Arch Ophthalmol       Date:  1994-05

8.  Unusual deposits in the superficial corneal stroma following combined use of topical corticosteroid and beta-blocking medication.

Authors:  W M Huige; W H Beekhuis; W J Rijneveld; N Schrage; L Remeijer
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

9.  Changes in mineral composition of rabbit corneas after alkali burn.

Authors:  T von Fischern; U Lorenz; W G Burchard; M Reim; N F Schrage
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1998-07       Impact factor: 3.117

10.  Conjunctival tissue examination in severe eye burns: a study with scanning electron microscopy and energy-dispersive X-ray analysis.

Authors:  G Schirner; N F Schrage; S Salla; M Reim; W G Burchard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-05       Impact factor: 3.117

View more
  7 in total

1.  [Chemical and thermal eye burns. Conservatíve and surgical options of a stage-dependent therapy].

Authors:  H G Struck; N F Schrage
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

2.  [Recommendations for acute treatment for chemical and thermal burns of eyes and lids].

Authors:  N F Schrage; H G Struck; M Gerard
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

3.  [Phosphate in ophthalmologic solutions].

Authors:  W Bernauer; M A Thiel; K M Rentsch
Journal:  Ophthalmologe       Date:  2006-05       Impact factor: 1.059

4.  Phosphate concentration in ophthalmic corticoid preparations.

Authors:  W Bernauer; M A Thiel; K M Rentsch
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-03-21       Impact factor: 3.117

5.  EDTA chelation for symptomatic band keratopathy: results and recurrence.

Authors:  A Al-Hity; K Ramaesh; D Lockington
Journal:  Eye (Lond)       Date:  2017-12-01       Impact factor: 3.775

6.  Assessment of Phosphate and Osmolarity Levels in Chronically Administered Eye Drops

Authors:  Onur Özalp; Eray Atalay; İbrahim Özkan Alataş; Zeynep Küskü Kiraz; Nilgün Yıldırım
Journal:  Turk J Ophthalmol       Date:  2019-06-27

Review 7.  Pathological Mineralization: The Potential of Mineralomics.

Authors:  Elena Tsolaki; Sergio Bertazzo
Journal:  Materials (Basel)       Date:  2019-09-25       Impact factor: 3.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.